拉米夫定XuWM,;16:94–103.(Pubmed)See1citationfoundusinganalternativesearch:JViralHepat. 2009Feb;16(2):94-:-:amulticentre,randomized,double-blind,placebo-,随机,双盲,安慰剂对照研究XuWM1, CuiYT, WangL, YangH, LiangZQ, LiXM, ZhangSL, QiaoFY, CampbellF, , GardnerS, ,double-blind,placebo-controlledstudyevaluatedwhetherlamivudinegivenduringlatepregnancycanreducehepatitisBvirus(HBV),,withagestationalageof26-30weeksandserumHBVDNA>1000MEq/mL(bDNAassay),-treatedmothers,ine+HBIg(lamivudine+ine+HBIg)ine(lamivudine+ine).Inplacebo-treatedmothers,ine+HBIg(placebo+ine+HBIg).Atweek52,intheprimaryanalyseswheremissingdatawascountedasfailures,infantsinthelamivudine+ine+HBIggrouphadasignificantdecreaseinincidenceofHBsAgseropositivity(10/56,18%vs23/59,39%;P=)andindetectableHBVDNA(11/56,20%vs27/59,46%;P=+ine+
抗病毒药物文献 来自淘豆网m.daumloan.com转载请标明出处.
